blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3313442

EP3313442 - ANTIBODIES AGAINST HUMAN CSF-1R FOR USE IN INDUCING LYMPHOCYTOSIS IN LYMPHOMAS OR LEUKEMIAS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.08.2020
Database last updated on 30.09.2024
FormerThe patent has been granted
Status updated on  13.09.2019
FormerGrant of patent is intended
Status updated on  11.09.2019
FormerExamination is in progress
Status updated on  30.08.2019
FormerGrant of patent is intended
Status updated on  22.04.2019
FormerExamination is in progress
Status updated on  19.10.2018
FormerRequest for examination was made
Status updated on  30.03.2018
FormerThe international publication has been made
Status updated on  30.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2018/18]
Inventor(s)01 / BERTILACCIO, Maria Teresa Sabrina
Via Washington 74
20146 Milano / IT
02 / CALIGARIS-CAPPIO, Federico
Nona Strada 6
San Felice
20090 Segrate / IT
03 / GALLETTI, Giovanni
Piazza Italia 3
20092 Cinisello Balsamo (MI) / IT
04 / KLEIN, Christian
Chapfstrasse 26B
8906 Bonstetten / CH
05 / RIES, Carola
St.-Klara-Strasse 9
82377 Penzberg / DE
 [2018/29]
Former [2018/18]01 / BERTILACCIO, Maria Teresa Sabrina
Via Washington 74
20146 Milano / IT
02 / CALIGARIS-CAPPIO, Federico
Nona Strada 6
San Felice
20090 Segrate / IT
03 / GALLETTI, Giovanni
Via Cassanese 200/c
20090 Segrate / IT
04 / KLEIN, Christian
Chapfstrasse 26B
8906 Bonstetten / CH
05 / RIES, Carola
St.-Klara-Strasse 9
82377 Penzberg / DE
Representative(s)Burger, Alexander, et al
Roche Diagnostics GmbH
Patentabteilung
Nonnenwald 2
82377 Penzberg / DE
[2019/42]
Former [2018/18]Burger, Alexander, et al
Roche Diagnostics GmbH Patent Department (LPP.....6164) P.O.Box 11 52
82372 Penzberg / DE
Application number, filing date16732589.323.06.2016
[2018/18]
WO2016EP64611
Priority number, dateEP2015017363824.06.2015         Original published format: EP 15173638
EP2016015112913.01.2016         Original published format: EP 16151129
[2018/18]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016207312
Date:29.12.2016
Language:EN
[2016/52]
Type: A1 Application with search report 
No.:EP3313442
Date:02.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 29.12.2016 takes the place of the publication of the European patent application.
[2018/18]
Type: B1 Patent specification 
No.:EP3313442
Date:16.10.2019
Language:EN
[2019/42]
Search report(s)International search report - published on:EP29.12.2016
ClassificationIPC:A61K39/395
[2018/18]
CPC:
C07K16/2866 (EP,KR,US); A61P35/02 (EP,US); C07K16/2887 (EP,KR,US);
A61K2039/505 (EP,KR,US); A61K2039/507 (EP,KR,US); C07K2317/24 (EP,KR,US);
C07K2317/73 (EP,KR,US); C07K2317/76 (EP,KR,US); C07K2317/90 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/18]
Extension statesBANot yet paid
MENot yet paid
Validation statesMA24.01.2018
TitleGerman:ANTIKÖRPER GEGEN MENSCHLICHES CSF-1R FÜR DIE INDUZIERUNG VON LYMPHOZYTOSE IN LYMPHOMEN ODER LEUKÄMIEN[2019/19]
English:ANTIBODIES AGAINST HUMAN CSF-1R FOR USE IN INDUCING LYMPHOCYTOSIS IN LYMPHOMAS OR LEUKEMIAS[2018/18]
French:ANTICORPS CONTRE LE CSF-1R HUMAIN PERMETTANT D'INDUIRE UNE LYMPHOCYTOSE DANS LES LYMPHOMES OU LES LEUCÉMIES[2019/19]
Former [2018/18]ANTIKÖRPER GEGEN MENSCHLICHES CSF-1R FÜR DIE INDUZIERUNG VON LYMPHOZYTOSE BEI LYMPHOMEN ODER LEUKÄMIEN
Former [2018/18]ANTICORPS CONTRE LE CSF-1R HUMAIN UTILISÉ POUR INDUIRE UNE LYMPHOCYTOSE DANS DES LYMPHOMES OU DES LEUCÉMIES
Entry into regional phase24.01.2018National basic fee paid 
24.01.2018Designation fee(s) paid 
24.01.2018Examination fee paid 
Examination procedure27.11.2017Amendment by applicant (claims and/or description)
27.11.2017Date on which the examining division has become responsible
24.01.2018Examination requested  [2018/18]
19.10.2018Despatch of a communication from the examining division (Time limit: M04)
01.02.2019Reply to a communication from the examining division
23.04.2019Communication of intention to grant the patent
27.08.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
27.08.2019Fee for grant paid
27.08.2019Fee for publishing/printing paid
11.09.2019Information about intention to grant a patent
11.09.2019Receipt of the translation of the claim(s)
Opposition(s)17.07.2020No opposition filed within time limit [2020/39]
Fees paidRenewal fee
08.06.2018Renewal fee patent year 03
10.06.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.06.2016
AL16.10.2019
AT16.10.2019
CY16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
MC16.10.2019
MK16.10.2019
MT16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SI16.10.2019
SK16.10.2019
SM16.10.2019
TR16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
IE23.06.2020
LU23.06.2020
BE30.06.2020
[2022/32]
Former [2022/27]HU23.06.2016
AL16.10.2019
AT16.10.2019
CY16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
MC16.10.2019
MT16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SI16.10.2019
SK16.10.2019
SM16.10.2019
TR16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
IE23.06.2020
LU23.06.2020
BE30.06.2020
Former [2021/24]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
MC16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SI16.10.2019
SK16.10.2019
SM16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
IE23.06.2020
LU23.06.2020
BE30.06.2020
Former [2021/20]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
MC16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SI16.10.2019
SK16.10.2019
SM16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
IE23.06.2020
LU23.06.2020
Former [2021/15]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
MC16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SI16.10.2019
SK16.10.2019
SM16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
LU23.06.2020
Former [2021/12]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
MC16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SI16.10.2019
SK16.10.2019
SM16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
Former [2020/51]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SI16.10.2019
SK16.10.2019
SM16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
Former [2020/38]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
IT16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SK16.10.2019
SM16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
Former [2020/37]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
SK16.10.2019
SM16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
Former [2020/36]AL16.10.2019
AT16.10.2019
CZ16.10.2019
DK16.10.2019
EE16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
IS16.02.2020
PT17.02.2020
Former [2020/35]AL16.10.2019
AT16.10.2019
CZ16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RO16.10.2019
RS16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
PT17.02.2020
IS24.02.2020
Former [2020/34]AL16.10.2019
AT16.10.2019
ES16.10.2019
FI16.10.2019
HR16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RS16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
PT17.02.2020
IS24.02.2020
Former [2020/32]AL16.10.2019
AT16.10.2019
FI16.10.2019
HR16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RS16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
PT17.02.2020
IS24.02.2020
Former [2020/25]AT16.10.2019
FI16.10.2019
HR16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
RS16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
PT17.02.2020
IS24.02.2020
Former [2020/24]AT16.10.2019
FI16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
PT17.02.2020
IS24.02.2020
Former [2020/23]AT16.10.2019
FI16.10.2019
LT16.10.2019
LV16.10.2019
NL16.10.2019
PL16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
GR17.01.2020
PT17.02.2020
Former [2020/22]FI16.10.2019
LT16.10.2019
NL16.10.2019
SE16.10.2019
BG16.01.2020
NO16.01.2020
PT17.02.2020
Former [2020/21]NL16.10.2019
NO16.01.2020
Former [2020/20]NL16.10.2019
Cited inInternational search[AD]WO2005044859  (GLYCART BIOTECHNOLOGY AG [CH], et al) [AD] 1-36 * paragraph [0018] * * paragraph [0033] ** paragraph [0241] *;
 [X]US2011243947  (DOODY JACQUELINE FRANCOISE [US], et al) [X] 1-5 * paragraph [0102] * * paragraph [0116] - paragraph [0119] *;
 [A]WO2013004806  (MORPHOSYS AG [DE], et al) [A] 1-36 * page 18, paragraph 2 *;
 [A]US2015073129  (HERTING FRANK [DE], et al) [A] 1-36 * paragraph [0013] * * examples 8,9 * * paragraph [0142] * * page 0234 * * paragraph [0238] * * claim 3 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.